Also found in: Dictionary.


trademark for preparations of goserelin, a gonadotropin suppressor used as an antineoplastic agent and to treat endometriosis.

goserelin acetate

Zoladex, Zoladex LA (CA) (UK), Zoladex 3-Month

Pharmacologic class: Gonadotropin-releasing hormone (GnRH) analog

Therapeutic class: Antineoplastic, hormone

Pregnancy risk category D (breast cancer), X (endometriosis)


Synthetic form of luteinizing hormone-releasing hormone (LHRH); inhibits gonadotropin production by acting directly on pituitary gland. Enhances release of luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone, lowering testosterone and estradiol levels.


Implant: 3.6 mg, 10.8 mg (in preloaded syringes)

Indications and dosages

Palliative treatment of advanced prostate cancer

Adults: 3.6 mg subcutaneously q 4 weeks or 10.8 mg subcutaneously q 12 weeks into upper abdominal wall

Adjunct to radiation therapy and flutamide in stage B2-C prostate cancer

Adults: 3.6 mg subcutaneously q 4 weeks starting on day 1 of radiation or during last week of radiation. Alternatively, 3.6 mg subcutaneously 8 weeks before radiation, then 10.8 mg on day 28 or 3.6 mg at 4-week intervals starting 8 weeks before radiation, for a total of four doses (two depots before and two during radiation therapy).

Palliative treatment of advanced breast cancer in pre- and perimenopausal women

Adults: 3.6 mg subcutaneously q 4 weeks. If serum estradiol doesn't fall to postmenopausal levels, may increase to 7.2 mg q 4 weeks.


Adults ages 18 and older: 3.6 mg subcutaneously q 4 weeks, continued for 6 months

Endometrial thinning before ablation for dysfunctional uterine bleeding

Adults: 3.6 mg subcutaneously 4 weeks before surgery. Alternatively, initial 3.6-mg dose may be followed 4 weeks later by a second 3.6-mg dose, with surgery 2 to 4 weeks after second dose.


• Hypersensitivity to drug or its components or to GnRH, GnRH agonist analogs

• Pregnant patients


Use cautiously in:

• risk factors for osteoporosis

• chronic alcohol or tobacco use

• patients receiving drugs that affect bone density

• hyperglycemia, cardiovascular risk factors

• breastfeeding patients

• children younger than age 18 (safety not established).


• Administer pretreatment pregnancy test to female of childbearing age.

• Know that drug should be given only by a clinician experienced in its use.

• Implant is placed subcutaneously into upper abdominal wall using aseptic technique. Give local anesthetic and stretch skin with one hand. Insert needle into subcutaneous fat, then change needle angle until it parallels abdominal wall. Push needle in until hub touches patient's skin, and withdraw about 1 ml before depressing plunger all the way.

• Don't aspirate after inserting needle. Blood will be visible in syringe if needle enters blood vessel.

Don't give by I.V. route.

• Be aware that 10.8-mg implant should not be used in women.

• Be aware that if implant must be removed, it can be located by ultrasound.

Adverse reactions

CNS: headache, anxiety, depression, dizziness, fatigue, insomnia, lethargy, pain, emotional lability, weakness, cerebrovascular accident, spinal cord compression

CV: vasodilation, chest pain, hypertension, palpitations, peripheral edema, myocardial infarction, arrhythmias, sudden cardiac death

EENT: blurred vision

GI: nausea, vomiting, diarrhea, constipation, ulcer, anorexia

GU: urinary obstruction, lower urinary tract symptoms, breast swelling or tenderness, vaginitis, amenorrhea, infertility, decreased libido, erectile dysfunction, other sexual dysfunction, decreased testicular size, renal insufficiency

Hematologic: anemia

Musculoskeletal: increased bone pain, joint pain, decreased bone density

Metabolic: gout, hyperglycemia, hypercalcemia

Respiratory: dyspnea, chronic obstructive pulmonary disease, upper respiratory tract infection

Skin: rash, acne, diaphoresis, seborrhea

Other: hirsutism, chills, fever, hot flashes, infection, weight gain, tumor flare phenomenon, hypersensitivity, antibody formation, acute anaphylactic reactions


Drug-diagnostic tests. Calcium, glucose, high- and low-density lipoproteins, triglycerides: increased levels

FSH, LH: initially increased, then decreased, levels

Patient monitoring

• Assess menstrual symptoms and watch for breakthrough bleeding.

Monitor neurologic status. Watch closely for signs and symptoms of cerebrovascular accident.

Closely monitor cardiovascular and respiratory status.

• Monitor blood glucose and glycosylated hemoglobin periodically.

Patient teaching

• Advise female patient to avoid pregnancy and to use a nonhormonal contraceptive method.

• Instruct patient to call prescriber if menstrual bleeding persists or breakthrough bleeding occurs.

• Inform patient that menstruation may be delayed after therapy ends.

Instruct patient to recognize and immediately report signs and symptoms of hyperglycemia, and cardiovascular or neurological adverse reactions.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.


A trademark for the drug goserelin acetate.


Goserelin acetate implant, see there.


A brand name for GOSERELIN.
References in periodicals archive ?
His son said: "Because his medical plan was not transferred to Stansty, a result of this was he did not receive his zoladex injections.
She then endured four months of chemotherapy, six weeks of radiotherapy and was put on the drugs Zoladex and Tamoxifen, king for which she has to keep takthe next five to10 years.
The development, at the firm's plant in Macclesfield, Cheshire, will lead to continued production of Zoladex, an injectable treatment for patients with prostate cancer.
After my chemotherapy ended, I could choose to take five years of an oral hormonal drug called Tamoxifen, or I could suppress my ovaries by taking a drug called Lupron or Zoladex and take five years of an Aromatase Inhibitor such as Letrozole (brand name Femara), Exemestane (Aromasin), or Anastrozole (Arimidex), or I could take five years of Tamoxifen and follow it up with another five years of an Aromatase Inhibitor.
GnRHs, which include Eligard, Lupron, Synarel, Trelstar, Vantas, Viadur, Zoladex and several generic options, block testosterone production by the testicles, with the result that almost no testosterone circulates in the body.
The Anglo-Swedish pharma major will pay USD13m to two classes of plaintiffs -- third-party payers who paid some or all of their Medicare co-insurance for its cancer drug Zoladex and/or its asthma treatment Pulmicort Respules in the northeastern US state of Massachusetts as well as consumers and third-party payers who paid cash or a co-pay for these drugs outside of Medicare in Massachusetts.
Medications in the GnRH class are marketed under the brand names Eligard, Lupron, Synarel, Trelstar, Vantas, Viadur, and Zoladex.
The drugs cited by the FDA include Zoladex from AstraZeneca; Trelstar from Watson; Vantas from Endo Pharmaceuticals Inc.
The downside of these strategies, however, is that they can deprive countries of patented technologies; several years ago AstraZeneca responded to pressures from the New Zealand government to lower prices for Zoladex by announcing that they would simply stop selling the drug in that market.